Abstract. Hepatocellular carcinoma (HCC) is the second leading cause of cancer-associated mortality worldwide in men. Bone marrow-derived cells (BMDCs), including circulating endothelial progenitor cells, have been reported to be involved in the progression of HCC. The complexity of BMDCs inspires further interest in the study of HCC. In the present study, highly metastatic HCC models with BM function deficiency/reconstruction were established by sublethal irradiation/BM transplantation. 
Introduction
In men, liver cancer is the second leading cause of cancer-associated mortality worldwide. The majority of primary liver cancers are hepatocellular carcinoma (HCC). Furthermore, ~50% of HCC cases and the associated fatalities occur in China (1) . The high rates of recurrence and metastasis exhibit a major impact on long-term survival, even in patients who have undergone radical resection or ablation. In fact, there is a noticeable lack of biomarkers that could effectively serve as predictive parameters for HCC patients. Several previous studies have shown that circulating endothelial progenitor cells (EPCs), a subpopulation of bone marrow-derived cells (BMDCs), could be used as a prognostic marker in patients with HCC (2) (3) (4) (5) . Moreover, it has been found that BM-derived multipotent progenitor cells may differentiate into endothelial cells and be recruited to partake in tumor vasculogenesis (6) , while the inhibition of vasculogenesis may markedly inhibit tumor growth (7, 8) . The complexity of BMDCs inspires further interest in the study of HCC.
Accumulating evidence has suggested that BMDCs play an important role in promoting tumor progression, including the incorporation of EPCs into the growing vasculature, and in subpopulations of BMDCs contributing to tumor neovascularization by providing growth factors, cytokines or other proangiogenic molecules (9) . A novel mechanism has been proposed in which BMDCs participate in initiating a microenvironment that fosters the recruitment of disseminating tumor cells prior to the arrival of metastatic tumor cells at distant organ sites (10, 11) . At these sites, termed as pre-metastatic niches, clusters of BM-derived hematopoietic progenitors prime distant tissues for the influx of tumor cells and the establishment of metastatic lesions (12, 13) . However, the controversy over the underlying mechanism never ends. For example, certain studies have shown that the blockade of vascular endothelial growth factor receptor-1 (VEGFR1) activity in BMDCs, which is believed by others to be a requisite in the regulation of metastasis (10), neither prevents nor changes the rate of spontaneous metastasis formation following primary tumor removal (14) .
Du et al reported that BM-derived CD45 + myeloid cells are essential for tumor metastasis, in which HIF1α contributes to the induction of SDF1α in tumor cells that in turn promotes tumor progression by recruiting vascular modulatory BMDCs to stimulate angiogenesis (15 Ahn and Brown found that tumors could not grow in matrix metalloproteinase-9-knockout mice, but that CD11b + myelomonocytic cells from the transplanted BM was able to restore tumor growth (16) . Due to the diversity of BMDCs, the role of other subtypes of BMDCs is a research hotspot. For example, data have shown that the predominant portion of EPCs in growing tumor vessels derived from the BM are CD45 -
VEGFR2
+ CD133 + c-kit + cells (17) , whereas the largest and most heterogeneous group of BMDCs in tumors consists of CD45 + myelocytic cells that contribute directly to neovascularization by expressing a variety of proangiogenic cytokines, growth factors and proteases (18) . It has been demonstrated that the VEGF family is extremely important for angiogenesis, and that myeloid-derived VEGF-A is essential to VEGFR2 in inhibiting tumor progression (19) . Sublethal irradiation does harm to the hematopoiesis of the BM, in which VEGFR2/3 are the main factors responsible for the recovery of homeostasis (20) . However, a number of unknown factors remain with regard to BMDCs.
In the present study, HCC models with BM function deficiency/reconstruction were established by sublethal irradiation/BM transplantation (BMT). (21) . HCC tumor models were established in nude mice by subcutaneous or orthotopic inoculation of 1.0x10 6 cells in 0.2 ml NaCl solution (0.9%), as previously described (22) . At the end of 9th week, the mice were sacrificed by cervical dislocation. The tumors were collected for the subsequent analysis.
Irradiation and BMT. The sensitivity of the athymic BALB/c nu/nu mice to whole-body irradiation was characterized through longitudinal studies first, using different doses of radiation (from 5 to 9 Gy). Next, BMT was performed after use of strain-specific sublethal doses of radiation (6.5 Gy) to ensure a high degree of chimerism. BM was harvested from donor BALB/c nu/nu mice. The VEGFR2 + fraction from the total BMDC population was magnetically isolated using magnetic beads conjugated with rat monoclonal anti-mouse VEGFR2 antibody (CD309 MicroBead kit; catalogue no. 130-097-346; Miltenyi Biotec, Inc., Cambridge, CA, USA 
Results

CD45
+ and VEGFR2 + BMDCs facilitate the recovery of BM function and promote tumor growth. In order to determine the optimal dose of irradiation, nude mice were pretreated with 9, 8, 7, 6.5 and 6 Gy, respectively. It was observed that the mice receiving 9, 8 or 7 Gy irradiation succumbed within 3-7 days of being irradiated. However, 6.5 Gy irradiation caused efficient BM inhibition without mortality and was chosen as the dose for the further experiments (data not shown).
HE staining in the peripheral blood and the BM smear demonstrated that, to a certain extent, the recovery of BM function was observed in all the different transplantation groups. The ratio of naive to mature cells was significantly different among all groups in the peripheral blood and the BM. The naive cells were more common in the VEGFR2-BMT group (Fig. 2) . The growth of the mice was not significantly affected (P=0.108). However, the tumor growth was markedly suppressed in the VEGFR2-BMT group (Fig. 3) . These data suggested that sublethal irradiation inhibited the tumor growth. However, it was the subpopulation of VEGFR2 -CD45 + cells, but not the VEGFR2 + BMDCs that facilitated tumor progression.
Enhancement of tumor growth by VEGFR2
-CD45 + BMDCs is independent of VEGFR2 + BMDCs. Magnetic beads were used to isolate the VEGFR2 + BMDCs, which was followed by CD45 + BMDC selection. The VEGFR2 + and VEGFR2 -CD45 + BMDCs were used for subtype BMT. At 5 weeks post-tumor inoculation in situ and subcutaneously, the expression of CD31 was detected by immunofluorescence (22) . The results showed that CD31 expression was found in all tumors obtained from the four groups. Microvessel density (MVD), however, was different among the groups. The lowest MVD was found in the tumors from the VEGFR2-BMT mice, whereas the difference was not significant in the other three groups (Fig. 4) . Since the VEGFR2 + BMDCs had been separated out beforehand in the CD45-BMT mice, a potential transdifferentiation of CD45 + BMDCs may have existed, which accounted for the origin of the VEGFR2 + endothelial precursors and the subsequent mature endothelial cells in the tumor vasculature.
Tumor cells and the liver microenvironment are indispensable to the expression of PDGFRα in the tumor endothelium.
Immunofluorescence staining was performed in in situ and subcutaneous tumors. The positive expression of PDGFRα was only observed in tumors in situ. Meanwhile, the MVD decreased in the subcutaneous tumors. Although the MVD was dramatically different in each of the groups with a different The recipient mice were sublethally irradiated (6.5 Gy) 24 h prior to the BMT. The irradiated mice received 2.0x10 6 BM cell suspensions through the tail vein and were allowed to recover for 4 weeks. In situ HCC models were then set up in the recipient mice, and the BM and peripheral blood were collected from the recipient mice on weeks 0, 1, 3, 5 and 7. Tumors were harvested on the 5th week. BM, bone marrow; BMT, BM transplantation; BMDCs, BM-derived cells; VEGFR2, vascular endothelial growth factor receptor-2; CD, cluster of differentiation.
A B
BMT, the expression of PDGFRα was universal (Fig. 5) . We have previously shown that the overexpression of PDGFRα in tumor endothelial cells is closely associated with the metastatic potential of HCC (22) . The present data suggested that not only the tumor cells, but also the liver microenvironment is indispensable to the expression of metastasis-related endothelial markers. (Fig. 6 ). These data suggested that vasculogenesis played an important role during the early and middle phase of tumor growth, while angiogenesis was the major determinant of HCC progression.
Synergistic effects of BM-derived
Discussion
In tumors, new blood vessels develop not only from pre-existing vessels (angiogenesis), but can also be formed from circulating vascular progenitor cells originating from the BM (vasculogenesis). There is a large amount of evidence demonstrating that EPCs and proangiogenic hematopoietic cells are able to support the vascularization of tumors and play a synergistic It has been demonstrated that EPCs exhibit their effects in the early stage of tumor formation (26, 27) . A recent study showed that EPCs were incorporated into the tumor vasculature with a 20-35% efficiency on days 4-6 post-tumor implantation, but then became diluted by local non-BM-derived endothelial cells, thus resulting in only 1% of EPCs being detected in the tumor vasculature following 4 weeks of growth (28) . The present data indicated that VEGFR2 + CD133 + cells played an important role in the middle stage of HCC tumor growth. This is consistent with the current notion that the BMDCs confer a promotional role on the existing blood vessels rather than de novo neovascularization in tumors, which is hypothesized to be a result of the highly proangiogenic features of these cells (23) .
In addition to EPCs, other types of BMDCs, such as myeloid cells, also contribute essentially to tumor progression. Myeloid cells are hematopoietic cells that are positive for VEGFR1 and eventually give rise to macrophages, monocytes and granulocytes/neutrophils. The cells share similar features with EPCs in that they may express endothelial specific markers, including CD31, CD34 and VEGFR2 under certain circumstances. A recent study illustrated that in breast and lung carcinoma models, the recruitment of myeloid cells, but not EPCs, facilitates tumor regrowth after local irradiation (29) , while the inhibition of vasculogenesis, instead of angiogenesis by blocking BMDC influx into the tumors, prevents the recurrence of glioblastoma following irradiation (8) . The present data showed that the transplantation of VEGFR2 -CD45 + BMDCs not only guaranteed the growth of the mice but also promoted the growth of the tumors. Even the expression of PDGFRα, a specific endothelial marker of HCC metastasis (22) may be the target for the inhibition of metastasis for late-stage HCC, while VEGFR2 + CD133 + cells may be a good choice for early-and middle-stage intervention. Finally, the present study found that sublethal irradiation, which attenuates the growth of the tumor, may offer a novel strategy for cancer treatment.
In conclusion, BMDCs play an important role in HCC progression. Different types of BMDCs may synergistically exhibit effects on HCC tumor growth and metastasis. The stage of tumor should be considered when targeting BMDCs.
